{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011909","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.970950+00:00","generated_at":"2026-05-17T07:38:52.479812+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Aprea Therapeutics files updated corporate slide deck; no material new data disclosed","bullets":["Filed updated corporate presentation dated September 2025 under Item 8.01.","Presentation titled 'Precision Oncology Through Synthetic Lethality' continues DDR inhibition focus.","No specific financial, clinical, or pipeline milestones were evident from the excerpt provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011909","json":"https://secwatch.observer/filing/0001558370-25-011909.json","markdown":"https://secwatch.observer/filing/0001558370-25-011909.md","text":"https://secwatch.observer/filing/0001558370-25-011909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025011909/0001558370-25-011909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025011909/apre-20250908x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:38:52.479812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}